-
公开(公告)号：US11992479B2
公开(公告)日：2024-05-28
申请号：US17052359
申请日：2019-05-02
申请人： DAMIAN PHARMA AG
IPC分类号： A61K31/473 , A61K31/437 , A61P5/00
CPC分类号： A61K31/437 , A61P5/00
摘要： The present invention relates to a composition for use in the treatment of a disease or disorder, wherein said disease or disorder is preferably a disease or disorder in which aldosterone overexposure contributes to the symptoms of said disease or disorder, said composition comprises a compound which is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine or a pharmaceutically acceptable salt thereof, wherein preferably said compound is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[1,5-a]pyridine dihydrogen phosphate, and wherein said compound has an enantiomeric excess (ee) of the (R) form higher than or equal to 97%, and wherein said composition is administered once daily to a subject in need thereof. The invention further relates to a pharmaceutical composition comprising a daily dosage of said compound in a fixed-unit dosage form and to a combination comprising (i) said pharmaceutical composition or said compound; and (ii) instructions for administration of said pharmaceutical composition or said compound once per day.
-
公开(公告)号：US11980597B2
公开(公告)日：2024-05-14
申请号：US18193207
申请日：2023-03-30
申请人： Duke University
IPC分类号： A61K31/138 , A61K9/00 , A61K9/70 , A61K31/00 , A61K31/192 , A61K31/40 , A61K45/06 , A61P5/00 , A61P35/00 , A61P35/04 , C12Q1/6827 , C12Q1/6886
CPC分类号： A61K31/138 , A61K9/0036 , A61K9/0053 , A61K9/7023 , A61K31/00 , A61K31/192 , A61K31/40 , A61K45/06 , A61P5/00 , A61P35/00 , A61P35/04 , C12Q1/6827 , C12Q1/6886 , C12Q2600/112 , C12Q2600/156
摘要： The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
-
公开(公告)号：US11964053B2
公开(公告)日：2024-04-23
申请号：US17828412
申请日：2022-05-31
申请人： Therio, LLC
发明人： John L. Curtis
CPC分类号： A61K9/1647 , A61K9/0019 , A61K9/10 , A61K9/5031 , A61K38/24 , A61P5/00
摘要： Methods and formulations for a simplified, single-injection method to induce and control the synchronous growth (superstimulation), and ovulation (superovulation) of multiple ovarian follicles in bovine, ovine, caprine, camelid and other female animals enabling the subsequent collection of (a) multiple oocytes when conducting in-vitro fertilization, or (b) multiple embryos when conducting multiple ovulation embryo transfer.
-
公开(公告)号：US20230414627A1
公开(公告)日：2023-12-28
申请号：US18307718
申请日：2023-04-26
发明人： Alexis HOWERTON , Hal GERBER , Michael HUANG
IPC分类号： A61K31/5377 , A61P5/24 , A61K31/573 , A61K9/48 , A61P5/00 , A61K9/14 , C07D487/04 , A61P5/38
CPC分类号： A61K31/5377 , A61P5/24 , A61K31/573 , A61K9/4825 , A61K9/48 , A61P5/00 , A61K9/14 , C07D487/04 , A61P5/38
摘要： The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
-
公开(公告)号：US11845715B2
公开(公告)日：2023-12-19
申请号：US17405989
申请日：2021-08-18
申请人： THE UNIVERSITY OF QUEENSLAND , THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
发明人： Luke O'Neill , Rebecca Coll , Matthew Cooper , Avril Robertson , Kate Schroder
IPC分类号： C07C311/56 , A61P17/00 , C07D403/12 , C07D249/12 , C07D249/04 , C07D241/42 , A61P25/00 , A61P37/00 , C07D495/04 , C07D241/44 , C07D277/36 , C07D307/68 , C07D487/04 , C07D215/36 , C07D249/06 , C07D311/16 , C07D401/06 , C07D401/12 , A61P3/00 , C07C311/60 , C07D213/71 , C07D217/22 , C07D221/18 , C07D317/62 , C07D333/34 , A61P1/00 , A61P35/00 , C07D217/02 , C07D241/24 , C07D271/12 , C07D413/12 , C07D417/12 , A61P5/00 , C07D307/18 , C07D307/64 , C07D311/60 , C07D333/52 , C07D333/62 , C07D405/12 , C07D495/06 , C07D217/24 , C07D235/02 , C07D311/18 , C07D407/12 , C07D231/18 , C07D307/82 , C07D309/08 , C07D493/04 , C07D207/38 , C07D261/18 , C07D498/04
CPC分类号： C07C311/56 , A61P1/00 , A61P3/00 , A61P5/00 , A61P17/00 , A61P25/00 , A61P35/00 , A61P37/00 , C07C311/60 , C07D207/38 , C07D213/71 , C07D215/36 , C07D217/02 , C07D217/22 , C07D217/24 , C07D221/18 , C07D231/18 , C07D235/02 , C07D241/24 , C07D241/42 , C07D241/44 , C07D249/04 , C07D249/06 , C07D249/12 , C07D261/18 , C07D271/12 , C07D277/36 , C07D307/18 , C07D307/64 , C07D307/68 , C07D307/82 , C07D309/08 , C07D311/16 , C07D311/18 , C07D311/60 , C07D317/62 , C07D333/34 , C07D333/52 , C07D333/62 , C07D401/06 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/12 , C07D413/12 , C07D417/12 , C07D487/04 , C07D493/04 , C07D495/04 , C07D495/06 , C07D498/04 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2602/08 , C07C2602/10 , C07C2603/10
摘要： The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.
-
公开(公告)号：US20190201455A1
公开(公告)日：2019-07-04
申请号：US16314471
申请日：2017-06-30
发明人： Mari DEZAWA , Michiaki UNNO , Toshihiro YAMAMOTO , Yasuhiro SHINDO , Hiroto HARA , Naoya MASUTOMI
IPC分类号： A61K35/545 , A61K35/28 , A61P1/16 , A61P17/02 , A61P11/00
CPC分类号： A61K35/545 , A61K35/28 , A61P1/00 , A61P1/16 , A61P5/00 , A61P9/00 , A61P11/00 , A61P13/00 , A61P15/00 , A61P17/00 , A61P17/02 , A61P25/00
摘要： An object of the present invention is to provide a safe and easy-to-prep cell product for prevention and/or treatment of organ fibrosis such as liver fibrosis. Provided is a cell product for prevention and/or treatment of organ fibrosis such as liver fibrosis, the cell product comprising a SSEA-3-positive pluripotent stem cell (Muse cell) derived from mesenchymal tissue in a living body or a cultured mesenchymal cell.
-
公开(公告)号：US20190185855A1
公开(公告)日：2019-06-20
申请号：US16322212
申请日：2017-08-11
发明人： Anastasia KHVOROVA , Mehran NIKAN , Matthew HASSLER , Maire OSBORN , Reka HARASZTI , Andrew COLES , Anton TURANOV , Neil ARONIN , Annabelle BISCANS
IPC分类号： C12N15/113 , A61K9/00 , A61P13/12 , A61P1/16 , A61K47/54 , A61K47/55 , A61P5/00 , A61P9/00 , A61P11/00 , A61P1/00
CPC分类号： C12N15/113 , A61K9/0019 , A61K31/7088 , A61K47/54 , A61K47/543 , A61K47/549 , A61K47/551 , A61K47/554 , A61P1/00 , A61P1/16 , A61P5/00 , A61P9/00 , A61P11/00 , A61P13/12 , C07H21/00 , C07H21/02 , C07H21/04 , C12N15/111 , C12N2310/14 , C12N2310/312 , C12N2310/315 , C12N2310/346 , C12N2310/351 , C12N2310/3515 , C12N2320/32 , C12N2310/321 , C12N2310/3521 , C12N2310/322 , C12N2310/3533
摘要： Provided herein are conjugated oligonucleotides that are characterized by efficient and specific tissue distribution.
-
公开(公告)号：US20180221335A1
公开(公告)日：2018-08-09
申请号：US15939218
申请日：2018-03-28
申请人： Duke University
IPC分类号： A61K31/40 , A61K31/00 , A61P35/04 , C12Q1/6886 , A61K45/06 , A61P5/00 , A61K9/00 , A61P35/00
CPC分类号： A61K31/40 , A61K9/0053 , A61K31/00 , A61K45/06 , A61P5/00 , A61P35/00 , A61P35/04 , C12Q1/6886 , C12Q2600/112 , C12Q2600/156
摘要： The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
-
公开(公告)号：US20180092948A1
公开(公告)日：2018-04-05
申请号：US15563122
申请日：2016-04-01
申请人： AOBIOME LLC
发明人： Larry Weiss , David R. Whitlock
IPC分类号： A61K35/74 , A61K9/00 , A61K31/04 , A61K31/201 , A61K31/202 , A61P29/00 , A61K45/06 , A61P17/10 , A61P17/06 , A61P17/00 , A61P13/12 , A61P9/00 , A61P11/00 , A61P25/00 , A61P5/00 , C12P13/00 , C12Q1/04
CPC分类号： A61K35/74 , A61K8/99 , A61K9/0014 , A61K31/04 , A61K31/20 , A61K31/201 , A61K31/202 , A61K35/744 , A61K35/745 , A61K35/747 , A61K45/06 , A61K2800/10 , A61K2800/522 , A61P5/00 , A61P9/00 , A61P11/00 , A61P13/12 , A61P17/00 , A61P17/06 , A61P17/10 , A61P25/00 , A61P29/00 , A61Q19/00 , C12P13/008 , C12Q1/04 , A61K2300/00
摘要： This disclosure provides compositions containing ammonia oxidizing bacteria and methods of use, including treatment of disorders related to inflammation. Also provided are compositions containing nitro-fatty acids and nitro-hydrocarbons and methods of generating same using ammonia oxidizing bacteria.
-
公开(公告)号：US20170128625A1
公开(公告)日：2017-05-11
申请号：US15182804
申请日：2016-06-15
IPC分类号： A61L27/38 , A61L27/16 , A61L27/54 , C12N5/0783 , C12N5/00 , C12N5/078 , C12N5/071 , C12N5/0789 , C12N5/073 , A61L27/36 , C12N5/0784
CPC分类号： A61L27/3804 , A61K31/167 , A61K31/192 , A61K31/616 , A61K35/12 , A61K35/22 , A61K35/39 , A61K35/407 , A61K35/50 , A61K35/51 , A61K35/55 , A61K38/13 , A61K45/06 , A61L27/16 , A61L27/3625 , A61L27/3683 , A61L27/3691 , A61L27/3834 , A61L27/3886 , A61L27/48 , A61L27/54 , A61L2300/252 , A61L2300/41 , A61L2300/414 , A61L2300/416 , A61L2300/426 , A61L2300/43 , A61L2430/40 , A61P3/00 , A61P5/00 , A61P15/08 , C12N5/0062 , C12N5/0605 , C12N5/0617 , C12N5/0639 , C12N5/0646 , C12N5/0647 , C12N5/065 , C12N2533/92 , C08L89/00 , A61K2300/00
摘要： Provided herein are organoids comprising decellularized placental vascular scaffold comprising, or consisting of, a decellularized placental vascular scaffold, and methods of making and using the same.
-
-
-
-
-
-
-
-
-
搜索结果
65 条记录 (耗时 0.028 秒)
